<DOC>
	<DOCNO>NCT00203450</DOCNO>
	<brief_summary>The primary objective study compare efficacy zonisamide ( Zonegran ; 100mg - 400mg/day ) placebo adjunctive agent lower weight subject body mass index ( BMI ) &gt; 25 psychotropic medication know side effect weight gain .</brief_summary>
	<brief_title>Zonegran Treatment Weight Gain Associated With Psychotropic Medication Use : A Placebo-Controlled Trial</brief_title>
	<detailed_description>After screen period , patient fulfil entrance criterion randomize 100mg zonisamide placebo 2:1 ratio respectively . Patients assessed baseline Weeks 2 , 4 , 8 , 12 , 16-post randomization weight , side effect , symptom . Symptoms assess Young Mania Rating Scale ( YMRS ) , Brief Psychiatric Rating Scale ( BPRS ) , Hamilton Depression Rating Scale ( HAMD ) , Hamilton Rating Scale Anxiety ( HARS ) , Self-report measure general health mental status baseline , week 2 , 4 , 8 , 12 , 16 . At conclusion study , patient taper study medication return primary provider continue treatment psychiatric condition .</detailed_description>
	<mesh_term>Weight Gain</mesh_term>
	<mesh_term>Zonisamide</mesh_term>
	<mesh_term>Psychotropic Drugs</mesh_term>
	<criteria>Are men woman , age 19 65 , inclusive Have diagnosis type bipolar disorder type psychotic disorder base structure diagnostic interview ( MINI ) . Are currently outpatient inpatient take neuroleptic mood stabilizer medication ( list ) past 6 month , stable dose past 2 month . Have body mass index &gt; 25 . No substance use disorder past 2 month ( except nicotine caffeine ) . Agree become pregnant study agree use adequate method birth control study barrier method , hormonal contraceptive , surgical sterilization ( female ) . All woman childbearing potential must negative pregnancy test begin study medication . Are able swallow capsule whole Are willing able follow Investigator instruction study procedure , report adverse event Not currently actively suicidal homicidal . No use topiramate within last 6 month . No medical contraindication use zonisamide . List medication inclusion criterion # 3 : All conventional neuroleptic . All atypical neuroleptic except aripiprazole ziprasidone . All form valproate . All form lithium . All form carbamazepine . Clinically significant renal hepatic disease . History acute intermittent porphyria , glucose6phosphate dehydrogenase deficiency hemolytic anemia . Allergy zonisamide sulfonamide . Have clinically unstable cardiovascular , hepatic , renal , gastrointestinal , pulmonary , metabolic , endocrine , systemic disease Have laboratory test result , opinion Investigator , clinically significant abnormality Require treatment medication ( e.g. , carbonic anhydrase inhibitor ) might interact adversely , obscure , action study drug Are pregnant lactating ( female ) Have history nephrolithiasis Refuse give inform consent Have previously enrol study previously treat zonisamide</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>obesity</keyword>
	<keyword>zonisamide</keyword>
	<keyword>zonegran</keyword>
	<keyword>psychotropic weight gain</keyword>
	<keyword>psychotropic</keyword>
</DOC>